Targetable "Driver" Mutations in Non Small Cell Lung Cancer

Indian Journal of Surgical Oncology

Volumn 2, Issue 3, 2011, Pages 178-188

  Vijayalakshmi, R ^a   Krishnamurthy, Arvind ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

Driver mutations; Molecular profiling based on mutations; Personalized therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; BEVACIZUMAB; BEZ 2235; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACOMITINIB; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; LAPATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAVELBINE; NERATINIB; PACLITAXEL; PEMETREXED; RAPAMYCIN; RIDAFOROLIMUS; RILOTUMUMAB; SELUMETINIB; SORAFENIB; TEMSIROLIMUS; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; DRUG TARGETING; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE;

EID: 84873245832     PISSN: 09757651     EISSN: 09766952     Source Type: Journal    
DOI: 10.1007/s13193-011-0108-0     Document Type: Review

References (79)

1. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer. N Engl J Med 355: 2542-2550.
2. Johnson D, Fehrenbacher L, Novotny W et al (2004) Randomised phase II trial comprising bevacizumab plus carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22: 2184-2191.
3. Grilley-Olson JE, Hayes D, Qaqish et al (2009) Diagnostic reproducibility of squamous cell carcinoma in the ear of the histology directed non-small cell chemotherapy: a large prospective study. J Clin Oncol 27, abstract 8008.
4. Herbst RS, Sandler A (2008) Bevacizumab and Erlotinib: a promising new approach to the treatment of advanced NSCLC. The Oncologist 13: 1166-1176.
5. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS (2006) K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 8: 30-38.
6. Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ (1999) Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 125: 61-70.
7. Salgia R, Skarin AT (1998) Molecular abnormalities in lung cancer. J Clin Oncol 16: 1207-1217.
8. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2003) Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 7398-7807.
9. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923.
10. Jänne PA (2005) Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol 32: S9-S15.
11. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501.
12. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865.
13. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha SG, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144.
14. Barker FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, Aldape KD (2001) EGFR overexpression and radiation response in glioblastoma multiforme Int J Radiat Oncol Biol Phys 51: 410-418.
15. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262.
16. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65: 7096-7101.
17. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 3: e73.
18. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7667.
19. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 10(23): 2493-2501.
20. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520.
21. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757.
22. Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, Wang SL, Wang MZ, Zhong W, Zhang L (2005) The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 16: 1334-1342.
23. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS (2011) Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, Epub ahead of print.
24. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefi tinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer - harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
25. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Eng J Med 361: 947-957.
26. Mitsudomi T (2009) Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR). Gan To Kagaku Ryoho 36: 1058-1062.
27. Lee JS, Park K, Kim SW (2009) A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung. 13th World Conference on Lung Cancer, San Francisco, July 31-August 4, 2009 (abstr PRS. 4).
28. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
29. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23: 8081-8092.
30. Yang C, Shih J, Su W et al (2010) Phase II study of BIBW2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol (Meeting abstracts) 28: 7521.
31. Boyer MJ, Blackhall FH, Park et al (2010) Efficacy and safety of PF299804 vs Erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). J Clin Oncol (Meeting Abstracts) 28: LBA 7523.
32. Mascausx C, Iannino N, Martin B et al (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139.
33. Shigematsu H, Takahashi T, Nomura M et al (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646.
34. Rodenhuis S, van de Wetering M, Mooi W, Evers S, van Zandwijk N, Bos J (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-935.
35. Ahrendt SA, Decker PA, Alawi EA et al (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530.
36. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734.
37. Mitsudomi T, Steinberg SM, Oie HK et al (1991) Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of the treatment intent. Cancer Res 51: 4999-5002.
38. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT (1999) Implications and prognostic value of KRAS mutation for early stage lung cancer in women. J Natl Cancer Inst 91: 2032-2038.
39. Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205.
40. Kakegawa S, Shimizu K, Sugano M, Miyamae Y, Kaira K, Araki T, Nakano T, Kamiyoshihara M, Kawashima O, Takeyoshi I (2011) Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer 2011. doi: 10. 1002/cncr. 26010.
41. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open label randomized phase III trial. Lancet 373: 1525-1531.
42. Soda M, Choi YL, Enomoto M, Takada S et al (2007) Identification of the transforming EML4-ALK fusion gene in non small cell lung cancer. Nature 448: 561-567.
43. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68: 4971-4976.
44. Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283.
45. Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small cell lung cancer. J Clin Oncol 27: 4247-4253.
46. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
47. Gridelli C, Maione P, Rossi A (2008) The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13: 139-147.
48. Bang Y, Kwak EL, Shaw AT et al (2010) Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28: 6s.
49. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H; ALK Lung Cancer Study Group (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739.
50. Stephens P, Hunter C, Bignell G et al (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
51. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10: 25-38.
52. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK (2009) HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106: 474-479.
53. De Greve J, Teugels E, De Mey J et al (2009) Clinical activity of BIBW2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu. J Thorac Oncol 4: S307 (abstr).
54. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D (2002) Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol 29: 10-16.
55. Sasaki H, Kawano O, Endo K et al (2006) Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133: 203-206.
56. Naoki K, Chen T-H, Richards WG, Sugarbaker DJ, Meyerson M (2002) Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62: 7001-7003.
57. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M (2009) EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15: 4554-4560.
58. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28: 1835-1842.
59. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
60. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059.
61. Gómez-Martín C, Rubio-Viqueira B, Hidalgo M (2005) Current status of mammalian target of rapamycin inhibitors in lung cancer. Clin Lung Cancer 1: S13-S18.
62. Molina JR, Mandrekar SJ, Rowland KR (2007) A phase II NCCTG"window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC. J Thorac Oncol 2(suppl 4): S413.
63. Papadimitrakopoulou V, Adjei AA (2006) The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol 1: 749-751.
64. Di Cosimo S, Ferretti G, Milella M, Martinelli E, Alimonti A, Papaldo P, Carlini P, Fabi A, Matar P, Cognetti F (2004) Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa). Minerva Med 5: 233-241.
65. Zou ZQ, Zhang XH, Wang F, Shen QJ, Xu J, Zhang LN, Xing WH, Zhuo RJ, Li D (2009) A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int J Mol Med 24: 97-101.
66. Ding L, Getz G, Wheeler DA et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
67. Malanga D, Scrima M, De Marco C et al (2008) Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7: 665-669.
68. Howe LR, Leevers SJ, Gómez N, Nakielny S, Cohen P, Marshall CJ (1992) Activation of the MAP kinase pathway by the protein kinase raf. Cell 71: 335-342.
69. Beau-Faller M, Ruppert AM, Voegeli AC et al (2008) MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 3: 331-339.
70. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T (2009) Activation of MET by gene amplification or by splice Mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4: 5-11.
71. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27: 1667-1674.
72. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937.
73. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
74. Cappuzzo F, Bemis L, Varella-Garcia M (2006) HER2 mutation and response to trastuzumab therapyin non-small-cell lung cancer. N Engl J Med 354: 2619-2621.
75. LoRusso P, Appleman L, Heath E, Malburg L, Zhu AX, Carey M, Shapiro GI, Eder JP (2006) Eur J Cancer Suppl 4: 141.
76. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15: 2207-2214.
77. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B (2007) Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 24: 1910-1918.
78. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66: 1721-1729.
79. Schiller JH, Akerley WL, Brugger W et al (2010) Results from ARQ 197-209: a global randomized placebo controlled phase II clinical trial o erlotinib plus ARQ 197 vs erlotinib plus placebo in previously treated EGFR inhibitor naïve patients with locally advanced or metastatic non small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 28: LBA 7502.